

## SUMMARY

The present disclosure provides antibodies, including multispecific (e.g. bispecific) antibodies, that bind to CD3 with good affinity and are resistant to degradation by e.g. asparagine deamidation and thus particularly stable as required for therapeutic purposes. The (multispecific) antibodies provided combine good efficacy (e.g. target cell killing) and produceability with low toxicity (e.g. no T cell activation in the absence of target cells) and favorable pharmacokinetic properties.

As is shown herein, the antibodies, including multispecific antibodies, that bind to CD3, provided by the present disclosure, retain more than about 95% binding activity to CD3 after 2 weeks at pH 7.4, 37°C, relative to the binding activity after 2 weeks at pH 6, -80°C, as determined by surface plasmon resonance (SPR).

In one aspect, the disclosure provides an antibody that binds to CD3, wherein the antibody comprises a first antigen binding domain, comprising

(i) a heavy chain variable region (VH) selected from the group consisting of

(a) a VH comprising a heavy chain complementary determining region (HCDR) 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 4, and a HCDR 3 of SEQ ID NO: 10,

(b) a VH comprising a HCDR 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 4, and a HCDR 3 of SEQ ID NO: 12,

(c) a VH comprising a HCDR 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 5, and a HCDR 3 of SEQ ID NO: 9,

(d) a VH comprising a HCDR 1 of SEQ ID NO: 3, a HCDR 2 of SEQ ID NO: 6, and a HCDR 3 of SEQ ID NO: 11, or

(e) a VH comprising a HCDR 1 of SEQ ID NO: 3, a HCDR 2 of SEQ ID NO: 7, and a HCDR 3 of SEQ ID NO: 13,

and

(ii) a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 20, a LCDR 2 of SEQ ID NO: 21 and a LCDR 3 of SEQ ID NO: 22.

In one example, the VH comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23.

In a further aspect, the disclosure provides an antibody that binds to CD3, wherein the antibody comprises a first antigen binding domain comprising a VH sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19, and a VL sequence of SEQ ID NO: 23.

5 In one example, the first antigen binding domain is a Fab molecule.

In one example, the antibody comprises an Fc domain composed of a first and a second subunit.

In one example, the antibody comprises a second and optionally a third antigen binding domain that binds to a second antigen.

10 In one example the second and/or, where present, the third antigen binding domain is a Fab molecule.

In one example the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH or the constant domains CL and CH1, particularly the variable domains VL and VH, of the Fab light chain and the Fab heavy chain are replaced by each other.

15 In one example the second and, where present, the third antigen binding domain is a conventional Fab molecule.

In one example, the second and, where present, the third antigen binding domain is a Fab molecule wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering  
20 according to Kabat), and in the constant domain CH1 the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

25 In one example, the first and the second antigen binding domain are fused to each other, optionally via a peptide linker.

In one example, the first and the second antigen binding domain are each a Fab molecule and either (i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, or (ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain  
30 of the second antigen binding domain.

In one example, the first, the second and, where present, the third antigen binding domain are each a Fab molecule and the antibody comprises an Fc domain composed of a first and a second subunit; and wherein either (i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain and the

first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain and the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and the third antigen binding domain, where present, is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

In one example, the Fc domain is an IgG, particularly an IgG<sub>1</sub>, Fc domain. In one example the Fc domain is a human Fc domain. In one example, the Fc comprises a modification promoting the association of the first and the second subunit of the Fc domain. In one example, the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.

In one example, the second antigen is a target cell antigen, particularly a tumor cell antigen.

In one example, the second antigen is TYRP-1. In one example, the second and, where present, the third antigen binding domain comprises a VH comprising a HCDR 1 of SEQ ID NO: 24, a HCDR 2 of SEQ ID NO: 25, and a HCDR 3 of SEQ ID NO: 26, and a VL comprising a LCDR 1 of SEQ ID NO: 28, a LCDR 2 of SEQ ID NO: 29 and a LCDR 3 of SEQ ID NO: 30. In one example, the second and, where present, the third antigen binding domain comprises a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 27, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31.

In one example, the second antigen is CEA. In one example, the second and, where present, the third antigen binding domain comprises (i) a VH comprising a HCDR 1 of SEQ ID NO: 53, a HCDR 2 of SEQ ID NO: 54, and a HCDR 3 of SEQ ID NO: 55, and a VL comprising a LCDR 1 of SEQ ID NO: 57, a LCDR 2 of SEQ ID NO: 58 and a LCDR 3 of SEQ ID NO: 59; (ii) a VH comprising a HCDR 1 of SEQ ID NO: 105, a HCDR 2 of SEQ ID NO: 106, and a HCDR 3 of SEQ ID NO: 107, and a VL comprising a LCDR 1 of SEQ ID NO: 109, a LCDR 2 of SEQ ID NO: 110 and a LCDR 3 of SEQ ID NO: 111; or (iii) a VH comprising a HCDR 1 of SEQ ID NO: 113, a HCDR 2 of SEQ ID NO: 114, and a HCDR 3 of SEQ ID NO: 115, and a VL comprising a LCDR 1 of SEQ ID NO: 117, a LCDR 2 of SEQ ID NO: 118 and a LCDR 3 of SEQ ID NO: 119. In one example, the second and, where present, the third antigen binding domain comprises (i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the

amino acid sequence of SEQ ID NO: 56, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 60; (ii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 108, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 112; or (iii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 116, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 120.

In one example, the second antigen is GPRC5D. In one example, the second and, where present, the third antigen binding domain comprises a VH comprising a HCDR 1 of SEQ ID NO: 61, a HCDR 2 of SEQ ID NO: 62, and a HCDR 3 of SEQ ID NO: 63, and a VL comprising a LCDR 1 of SEQ ID NO: 65, a LCDR 2 of SEQ ID NO: 66 and a LCDR 3 of SEQ ID NO: 67. In one example, the second and, where present, the third antigen binding domain comprises a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 64, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 68.

In one example, the second antigen is CD19. In one example, the second and, where present, the third antigen binding domain comprises (i) a VH comprising a HCDR 1 of SEQ ID NO: 75, a HCDR 2 of SEQ ID NO: 76, and a HCDR 3 of SEQ ID NO: 77, and a VL comprising a LCDR 1 of SEQ ID NO: 79, a LCDR 2 of SEQ ID NO: 80 and a LCDR 3 of SEQ ID NO: 81; or (ii) a VH comprising a HCDR 1 of SEQ ID NO: 83, a HCDR 2 of SEQ ID NO: 84, and a HCDR 3 of SEQ ID NO: 85, and a VL comprising a LCDR 1 of SEQ ID NO: 87, a LCDR 2 of SEQ ID NO: 88 and a LCDR 3 of SEQ ID NO: 89. In one example, the second and, where present, the third antigen binding domain comprises (i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 78, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 82; or (ii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 86, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 90.

There is provided an isolated polynucleotide encoding an antibody of the disclosure, and a host cell comprising the isolated polynucleotide of the disclosure. In another aspect, there is provided an isolated polynucleotide encoding the antibody of the disclosure. In another aspect, there is provided a host cell comprising the isolated polynucleotide of the disclosure.

5 In another aspect, there is provided a method of producing an antibody that binds to CD3, comprising the steps of (a) culturing the host cell of the disclosure under conditions suitable for the expression of the antibody and optionally (b) recovering the antibody. In another aspect, the disclosure also encompasses an antibody that binds to CD3 produced by the method of the disclosure.

10 In another aspect, the disclosure further provides a pharmaceutical composition comprising the antibody of the disclosure and a pharmaceutically acceptable carrier.

Also encompassed by the disclosure are methods of using the antibody and pharmaceutical composition of the disclosure. In another aspect, the disclosure provides the antibody according to the disclosure or the pharmaceutical composition according to the disclosure for use as a  
15 medicament. In another aspect, there is provided the antibody according to the disclosure or the pharmaceutical composition according to the disclosure for use in the treatment of a disease. In a specific example the disease is cancer.

Also provided is the use of an antibody or pharmaceutical composition according to the disclosure in the manufacture of a medicament, the use of an antibody or pharmaceutical composition  
20 according to the disclosure in the manufacture of a medicament for the treatment of a disease, particularly cancer. In another aspect, the present disclosure provides use of the antibody of the disclosure or the pharmaceutical composition of the disclosure in the manufacture of a medicament. In another aspect, the present disclosure provides use of the antibody of the disclosure or the pharmaceutical composition of the disclosure in the manufacture of a medicament for the treatment  
25 of a disease. The disclosure also provides a method of treating a disease in an individual, comprising administering to said individual an effective amount of the antibody or pharmaceutical composition according to the disclosure.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1.** Exemplary configurations of the (multispecific) antibodies of the invention. (A, D) Illustration of the “1+1 CrossMab” molecule. (B, E) Illustration of the “2+1 IgG Crossfab” molecule with alternative order of Crossfab and Fab components (“inverted”). (C, F) Illustration of the “2+1 IgG Crossfab” molecule. (G, K) Illustration of the “1+1 IgG Crossfab” molecule with alternative order of Crossfab and Fab components (“inverted”). (H, L) Illustration of the “1+1 IgG Crossfab” molecule. (I, M) Illustration of the “2+1 IgG Crossfab” molecule with two CrossFabs. (J, N) Illustration of the “2+1 IgG Crossfab” molecule with two CrossFabs and alternative order of Crossfab and Fab components (“inverted”). (O, S) Illustration of the “Fab-Crossfab” molecule. (P, T) Illustration of the “Crossfab-Fab” molecule. (Q, U) Illustration of the “(Fab)<sub>2</sub>-Crossfab” molecule. (R, V) Illustration of the “Crossfab-(Fab)<sub>2</sub>” molecule. (W, Y) Illustration of the “Fab-(Crossfab)<sub>2</sub>” molecule. (X, Z) Illustration of the “(Crossfab)<sub>2</sub>-Fab” molecule. Black dot: optional

## CLAIMS

1. An antibody that binds to CD3, wherein the antibody comprises a first antigen binding domain, comprising
  - (i) a heavy chain variable region (VH) selected from the group consisting of
    - 5 (a) a VH comprising a heavy chain complementary determining region (HCDR) 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 4, and a HCDR 3 of SEQ ID NO: 10,
    - (b) a VH comprising a HCDR 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 4, and a HCDR 3 of SEQ ID NO: 12,
    - (c) a VH comprising a HCDR 1 of SEQ ID NO: 2, a HCDR 2 of SEQ ID NO: 5, and a HCDR 3  
10 of SEQ ID NO: 9,
    - (d) a VH comprising a HCDR 1 of SEQ ID NO: 3, a HCDR 2 of SEQ ID NO: 6, and a HCDR 3 of SEQ ID NO: 11, or
    - (e) a VH comprising a HCDR 1 of SEQ ID NO: 3, a HCDR 2 of SEQ ID NO: 7, and a HCDR 3 of SEQ ID NO: 13,
  - 15 and
  - (ii) a light chain variable region (VL) comprising a light chain complementarity determining region (LCDR) 1 of SEQ ID NO: 20, a LCDR 2 of SEQ ID NO: 21 and a LCDR 3 of SEQ ID NO: 22.
2. The antibody of claim 1, wherein the VH comprises an amino acid sequence that is at least about  
20 95%, 96%, 97%, 98%, 99% or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19, and/or the VL comprises an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 23.
3. An antibody that binds to CD3, wherein the antibody comprises a first antigen binding domain  
25 comprising a VH sequence selected from the group consisting of SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 15, SEQ ID NO: 17 and SEQ ID NO: 19, and a VL sequence of SEQ ID NO: 23.
4. The antibody of any one of claims 1-3, wherein the first antigen binding domain is a Fab molecule.
5. The antibody of any one of claims 1-4, comprising an Fc domain composed of a first and a  
30 second subunit.
6. The antibody of any one of claims 1-5, comprising a second and optionally a third antigen binding domain that binds to a second antigen.

7. The antibody of claim 6, wherein the second and/or, where present, the third antigen binding domain is a Fab molecule.

8. The antibody of any one of claims 1-7, wherein the first antigen binding domain is a Fab molecule wherein the variable domains VL and VH or the constant domains CL and CH1, particularly the variable domains VL and VH, of the Fab light chain and the Fab heavy chain are replaced by each other.

9. The antibody of any one of claims 6-8, wherein the second and, where present, the third antigen binding domain is a conventional Fab molecule.

10. The antibody of any one of claims 6-9, wherein the second and, where present, the third antigen binding domain is a Fab molecule wherein in the constant domain CL the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat) and the amino acid at position 123 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the constant domain CH1 the amino acid at position 147 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index) and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to Kabat EU index).

11. The antibody of any one of claims 6-10, wherein the first and the second antigen binding domain are fused to each other, optionally via a peptide linker.

12. The antibody of any one of claims 6-11, wherein the first and the second antigen binding domain are each a Fab molecule and either (i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain, or (ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain.

13. The antibody of any one of claims 6-12, wherein the first, the second and, where present, the third antigen binding domain are each a Fab molecule and the antibody comprises an Fc domain composed of a first and a second subunit; and wherein either (i) the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding domain and the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain, or (ii) the first antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding domain and the second antigen binding domain is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain;

and the third antigen binding domain, where present, is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

14. The antibody of any one of claims 5-13, wherein the Fc domain is an IgG, particularly an IgG<sub>1</sub>, Fc domain.

5 15. The antibody of any one of claims 5-14, wherein the Fc domain is a human Fc domain.

16. The antibody of any one of claims 5-15, wherein the Fc comprises a modification promoting the association of the first and the second subunit of the Fc domain.

17. The antibody of any one of claims 5-16, wherein the Fc domain comprises one or more amino acid substitution that reduces binding to an Fc receptor and/or effector function.

10 18. The antibody of any one of claims 6-17, wherein the second antigen is a target cell antigen, particularly a tumor cell antigen.

19. The antibody of any one of claims 6-18, wherein the second antigen is TYRP-1.

20. The antibody of claim 19, wherein the second and, where present, the third antigen binding domain comprises a VH comprising a HCDR 1 of SEQ ID NO: 24, a HCDR 2 of SEQ ID NO: 25,  
15 and a HCDR 3 of SEQ ID NO: 26, and a VL comprising a LCDR 1 of SEQ ID NO: 28, a LCDR 2 of SEQ ID NO: 29 and a LCDR 3 of SEQ ID NO: 30.

21. The antibody of claims 19 or 20, wherein the second and, where present, the third antigen binding domain comprises a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 27, and/or a  
20 VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 31.

22. The antibody of any one of claims 6-18, wherein the second antigen is CEA.

23. The antibody of claim 22, wherein the second and, where present, the third antigen binding domain comprises

25 (i) a VH comprising a HCDR 1 of SEQ ID NO: 53, a HCDR 2 of SEQ ID NO: 54, and a HCDR 3 of SEQ ID NO: 55, and a VL comprising a LCDR 1 of SEQ ID NO: 57, a LCDR 2 of SEQ ID NO: 58 and a LCDR 3 of SEQ ID NO: 59;

(ii) a VH comprising a HCDR 1 of SEQ ID NO: 105, a HCDR 2 of SEQ ID NO: 106, and a HCDR 3 of SEQ ID NO: 107, and a VL comprising a LCDR 1 of SEQ ID NO: 109, a LCDR 2 of SEQ  
30 ID NO: 110 and a LCDR 3 of SEQ ID NO: 111; or

(iii) a VH comprising a HCDR 1 of SEQ ID NO: 113, a HCDR 2 of SEQ ID NO: 114, and a HCDR 3 of SEQ ID NO: 115, and a VL comprising a LCDR 1 of SEQ ID NO: 117, a LCDR 2 of SEQ ID NO: 118 and a LCDR 3 of SEQ ID NO: 119.

24. The antibody of claim 22 or 23, wherein the second and, where present, the third antigen binding domain comprises

(i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 56, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 60;

(ii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 108, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 112; or

(iii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 116, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 120.

25. The antibody of any one of claims 6-18, wherein the second antigen is GPRC5D.

26. The antibody of claim 25, wherein the second and, where present, the third antigen binding domain comprises a VH comprising a HCDR 1 of SEQ ID NO: 61, a HCDR 2 of SEQ ID NO: 62, and a HCDR 3 of SEQ ID NO: 63, and a VL comprising a LCDR 1 of SEQ ID NO: 65, a LCDR 2 of SEQ ID NO: 66 and a LCDR 3 of SEQ ID NO: 67.

27. The antibody of claims 25 or 26, wherein the second and, where present, the third antigen binding domain comprises a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 64, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 68.

28. The antibody of any one of claims 6-18, wherein the second antigen is CD19.

29. The antibody of claim 28, wherein the second and, where present, the third antigen binding domain comprises

(i) a VH comprising a HCDR 1 of SEQ ID NO: 75, a HCDR 2 of SEQ ID NO: 76, and a HCDR 3 of SEQ ID NO: 77, and a VL comprising a LCDR 1 of SEQ ID NO: 79, a LCDR 2 of SEQ ID NO: 80 and a LCDR 3 of SEQ ID NO: 81; or

(ii) a VH comprising a HCDR 1 of SEQ ID NO: 83, a HCDR 2 of SEQ ID NO: 84, and a HCDR 3 of SEQ ID NO: 85, and a VL comprising a LCDR 1 of SEQ ID NO: 87, a LCDR 2 of SEQ ID NO: 88 and a LCDR 3 of SEQ ID NO: 89.

30. The antibody of claim 28 or 29, wherein the second and, where present, the third antigen binding domain comprises

(i) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 78, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 82; or

(ii) a VH comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 86, and/or a VL comprising an amino acid sequence that is at least about 95%, 96%, 97%, 98%, 99% or 100% identical to the amino acid sequence of SEQ ID NO: 90.

31. An isolated polynucleotide encoding the antibody of any one of claims 1-30.

32. A host cell comprising the isolated polynucleotide of claim 31.

33. A method of producing an antibody that binds to CD3, comprising the steps of (a) culturing the host cell of claim 32 under conditions suitable for the expression of the antibody and optionally (b) recovering the antibody.

34. An antibody that binds to CD3 produced by the method of claim 33.

35. A pharmaceutical composition comprising the antibody of any one of claims 1-30 or 34 and a pharmaceutically acceptable carrier.

36. The antibody of any one of claims 1-30 or 34 or the pharmaceutical composition of claim 35 for use as a medicament.

37. The antibody of any one of claims 1-30 or 34 or the pharmaceutical composition of claim 35 for use in the treatment of a disease.

38. The antibody for use of claim 37, wherein the disease is cancer or an autoimmune disease.

39. Use of the antibody of any one of claims 1-30 or 34 or the pharmaceutical composition of claim 35 in the manufacture of a medicament.

40. Use of the antibody of any one of claims 1-30 or 34 or the pharmaceutical composition of claim 35 in the manufacture of a medicament for the treatment of a disease.

41. The use of claim 40, wherein the disease is cancer or an autoimmune disease.